|
Veeva、患者および処方データに関する新たなアプローチを提供するVeeva Data Cloudを発表
|
|
患者と処方データに関する新たなアプローチ、Veeva Data Cloudを発表
|
https://www.veeva.com/jp/news/veeva-data-cloud-to-deliver-new-approach-for-patient-and-prescriber-data/
|
|
|
|
|
|
Veeva Commercial Cloud: https://www.veeva.com/jp/products/commercial-cloud/
マルチチャネルVeeva CRM: https://www.veeva.com/jp/products/multichannel-crm/
MyVeeva for Doctors: https://veeva.jp/myveeva/doctors/
Veeva Data Cloud: https://www.veeva.com/jp/news/veeva-data-cloud-to-deliver-new-approach-for-patient-and-prescriber-data/
【Axsome Therapeutics社について】
Axsome Therapeutics社は、治療法の選択肢が限られた中枢神経系 (CNS) 疾患を抑制する新規治療法の開発を専門とするバイオ医薬品企業です。CNS疾患の治療法に満足できない多くの患者のために、Axsome社では人生を変える治療薬のより迅速な開発と普及に努めています。Axsome社のCNS向け主力製品群には、AXS-05、AXS-07、AXS-09、AXS-12、AXS-14の5つの臨床ステージ候補が含まれます。AXS-05は大うつ病性障害 (MDD)、アルツハイマー型認知症 (AD) の興奮症状、および禁煙の治療、AXS-07は片頭痛急性期治療、AXS-12はナルコレプシー (睡眠発作) の治療、AXS-14は線維筋痛症の治療のために開発が進められています。AXS-05、AXS-07、AXS-09、AXS-12、AXS-14は、いずれもFDA未承認の治験薬製品です。詳細は、Axsome社のWebサイト (https://axsome.com/) をご覧ください。Axsome社は重要な非公開情報を自社のWebサイトで公表することがあります。
【Veeva Systems社について】
Veeva Systems社はグローバルなライフサイエンス企業向けにクラウドベースのソフトウェアを提供するリーディングカンパニーです。世界最大規模の製薬会社からバイオテクノロジー分野の新興企業まで、900社を超える顧客に技術革新への取り組みや卓越した製品力によって、お客様の成功にコミットする様々なサービスを提供しています。Veevaは、サンフランシスコのベイエリアに本社を置き、ヨーロッパ、アジア、ラテンアメリカに拠点を展開しています。
詳しくは、https://veeva.com/jp/をご覧ください。
【Forward Looking Statements Regarding Axsome】 Therapeutics, Inc.
Certain matters discussed in this press release are “forward-looking statements”. Axsome may, in some cases, use terms such as “predicts,” “believes,” “potential,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. In particular, the Axsome’s statements regarding trends and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the success, timing and cost of Axsome’s ongoing clinical trials and anticipated clinical trials for Axsome’s current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including Axsome’s ability to fully fund our disclosed clinical trials, which assumes no material changes to Axsome’s currently projected expenses), futility analyses and receipt of interim results, which are not necessarily indicative of the final results of Axsome’s ongoing clinical trials, and the number or type of studies or nature of results necessary to support the filing of a new drug application (“NDA”) for any of Axsome’s current product candidates; Axsome’s ability to fund additional clinical trials to continue the advancement of Axsome’s product candidates; the timing of and Axsome’s ability to obtain and maintain U.S. Food and Drug Administration (“FDA”) or other regulatory authority approval of, or other action with respect to, Axsome’s product candidates (including, but not limited to, with or without a special protocol assessment); the potential for Axsome’s clinical trials to provide a basis for accelerated approval of Axsome’s product candidates for the treatment of several indications and accelerate their development timelines and commercial paths to patients (including, but not limited to, with or without a breakthrough therapy designation); Axsome’s ability to successfully defend its intellectual property or obtain the necessary licenses at a cost acceptable to Axsome, if at all; the successful implementation of Axsome’s research and development programs and collaborations; the success of Axsome’s license agreements; the acceptance by the market of Axsome’s product candidates, if approved; Axsome’s anticipated capital requirements, including Axsome’s anticipated cash runway and Axsome’s ability to fund Axsome’s commercial launch, which assumes product approval; unforeseen circumstances or other disruptions to normal business operations arising from or related to COVID-19; and other factors, including general economic conditions and regulatory developments, not within Axsome’s control. The factors discussed herein could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and Axsome undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance.
【Forward-looking Statements】
This release contains forward-looking statements, including the market demand for and acceptance of Veeva’s products and services, the results from use of Veeva’s products and services, and general business conditions (including the on-going impact of COVID-19), particularly within the life sciences industry. Any forward-looking statements contained in this press release are based upon Veeva’s historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Veeva’s expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Veeva disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect Veeva’s financial results are included under the captions, “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in the company’s filing on Form 10-Q for the period ended July 31, 2020. This is available on the company’s website at veeva.com under the Investors section and on the SEC’s website at sec.gov. Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time.